title: Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats.
abstract: The influence of the selective serotonin (5-HT) reuptake inhibiting antidepressant zimeldine and its metabolite norzimeldine was tested on experimental allergic neuritis (EAN) in Lewis rats, which is an animal model of the Guillain-Barré syndrome (GBS) in man. Zimeldine and norzimeldine both suppressed clinical signs of actively induced EAN when given at a dose of 20 mg/kg/day intraperitoneally via osmotic pumps. The effects of zimeldine, its metabolites norzimeldine and CPP 200 as well as of the antidepressants clomipramine, imipramine and maprotiline on in vitro immune response were tested. Thereby we used an immunospot assay for interferon-gamma (IFN-gamma) produced by lymph node mononuclear cells (MNC), which reflects number of memory T lymphocytes activated by antigen or lectin, in this experiment bovine peripheral nerve myelin (BPM) and phytohemagglutinin (PHA), respectively. In the IFN-gamma secretion assay zimeldine, CPP 200, clomipramine and maprotiline all in a concentration-dependent mode reduced the number of IFN-gamma secreting cells while norzimeldine and imipramine did not affect the IFN-gamma secretion. In assays for proliferation in response to antigen or lectin, the concentration 10(-4) M was judged toxic for all substances tested, and at concentrations below that all but zimeldine showed a dose-dependent slight reduction of MNC proliferation. The action of several drugs on induced T cell secretion of IFN-gamma suggests that the mechanisms for the suppressive effect of zimeldine and norzimeldine on EAN symptoms can be due to an action on myelin T cell autoreactivity. All the monoamine reuptake inhibiting antidepressants tested in this study showed immunomodulatory effects by either a reduction of the number of IFN-gamma-secreting cells or the MNC proliferation. These observations call for further studies of immunological mechanisms in the pathogenesis of mental disorders as well as on the potential role of drugs acting on the monoamine systems in the treatment of recognized autoimmune diseases.
authors.affiliation: Department of Psychiatry, Faculty of Health Sciences, University Hospital, Linköping, Sweden.
authors.forename: B O
authors.initials: BO
authors.lastname: Bengtsson
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: L H
authors.initials: LH
authors.lastname: Thorell
authors.forename: T
authors.initials: T
authors.lastname: Olsson
authors.forename: H
authors.initials: H
authors.lastname: Link
authors.forename: J
authors.initials: J
authors.lastname: Wålinder
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D007371:Interferon-gamma / Q000378:metabolism; D008198:Lymph Nodes / Q000473:pathology; D009000:Monocytes / Q000473:pathology; D009444:Neuritis, Autoimmune, Experimental / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D011917:Rats, Inbred Lew; D015031:Zimeldine / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D000928:Antidepressive Agents; D015031:Zimeldine; C017578:norzimelidine; D007371:Interferon-gamma